专利号:US-7781583-B2 优先权日:2006-09-08 标题:Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d] pryimidin-7-ones 发明人:ERDMAN DAVID THOMAS; FLAMME CATHLIN MARIE; NELSON JADE DOUGLAS 权利人:PFIZER 摘要:The present invention provides methods of preparing substituted 2-(pyridin-2-ylamino)-pirido[2,3-d]pyrimidin-7-ones (formula 1), n nuseful in treating cell proliferative disorders, or a pharmaceutically acceptable salt thereof.
专利号:US-2008125588-A1 优先权日:2006-09-08 标 题:SYNTHESIS OF 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3-d] PRYIMIDIN-7-ONES
1: Wu J, Wang J, O'Connor TN, Tzetzo SL, Gurova KV, Knudsen ES, Witkiewicz AK. Separable cell cycle arrest and immune response elicited through pharmacological CDK4/6 and MEK inhibition in RASmut disease models. Mol Cancer Ther. 2024 Aug 16. doi: 10.1158/1535-7163.MCT-24-0369. Epub ahead of print. 57:101039. doi: 10.1016/j.neo.2024.101039. Epub ahead of print. 24(1):185. doi: 10.1007/s10238-024-01458-1. 5: Lin W, Zeng Y, Weng L, Yang J, Zhuang W. Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study. BMC Pharmacol Toxicol. 2024 Aug 9;25(1):47. doi: 10.1186/s40360-024-00770-6.